Wy-14643 is a powerful PPARα agonist that can inhibit steatosis, restore insulin sensitivity, as well as lipid and adiponectin levels, thereby reducing MASLD caused by PPARα dysregulation (51). Here, ADIPOQ is linked to metabolic dysfunction-associated steatotic liver disease.